Eli Lilly And Company Announced Results Of The CHALLENGE-MIG Clinical Trial Of Emgality In Episodic Migraine Prevention; Did Not Achieve Statistical Superiority Versus Active Comparator On The Primary Endpoint
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly announced results of the CHALLENGE-MIG clinical trial of Emgality in episodic migraine prevention, which did not achieve statistical superiority versus active comparator Nurtec ODT on the primary endpoint. However, Emgality demonstrated robust efficacy and performed numerically better on key secondary endpoints.
June 16, 2023 | 4:04 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly's Emgality did not achieve statistical superiority in the CHALLENGE-MIG trial, but demonstrated robust efficacy and better secondary endpoints.
Although Emgality did not achieve statistical superiority in the primary endpoint, it demonstrated robust efficacy and performed better on key secondary endpoints. This mixed result may not have a significant short-term impact on Eli Lilly's stock price, as the drug still shows promise in migraine prevention.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100